收藏切换
"Uphold integrity and innovation, and seek well-being for people's health" Three highlights of the adjustment of national reimbursement drug list in 2021
收藏切换
Jinxi DING1, 2, Wei LI1, 2
World Clinical Drug | 2022, 43(1) : 1 - 4
Less
收藏切换
World Clinical Drug | 2022, 43(1): 1-4
• Recommendation •
"Uphold integrity and innovation, and seek well-being for people's health" Three highlights of the adjustment of national reimbursement drug list in 2021
Full
Jinxi DING1, 2, Wei LI1, 2
Affiliations
  • 1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
  • 2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
Published: 2022-01-10 doi: 10.13683/j.wph.2022.01.001
Outline
收藏切换

Since 2017, the national healthcare security administration (NHSA) has adjusted the national reimbursement drug list (NRDL) for five times. Normalized adjustment mechanism has been gradually established, and the negotiation mechanism has been increasingly improved. Especially in 2021, the NHSA, upholding integrity and innovation, made an all-round optimization of NRDL adjustment mechanism based on the full summary of the first four rounds of adjustment experience. This paper analyzed the policy optimization of NHSA in the fifth round of NRDL adjustment based on the practice of 2021 NRDL adjustment work, focusing on three aspects: access process, measurement mechanism, and adjustment principles. Furthermore, this paper summarized the experience and put forward development ideas to promote the further improvement of Chinese medical insurance system.

national reimbursement drug list  /  dynamic adjustment  /  policy optimization
丁锦希, 李伟. “守正创新,为人民健康谋福祉”谈2021年国家医保目录调整工作的三大亮点. 世界临床药物, 2022 , 43 (1) : 1 -4 . DOI: 10.13683/j.wph.2022.01.001
Jinxi DING, Wei LI. "Uphold integrity and innovation, and seek well-being for people's health" Three highlights of the adjustment of national reimbursement drug list in 2021[J]. World Clinical Drug, 2022 , 43 (1) : 1 -4 . DOI: 10.13683/j.wph.2022.01.001
Year 2022 volume 43 Issue 1
11
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.01.001
  • Receive Date:2021-12-04
  • Online Date:2026-11-19
  • Published:2022-01-10
Article Data
Affiliations
History
  • Received:2021-12-04
Affiliations
    1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
    2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.01.001
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT